Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Ubrogepant

FDA-approved product (tablet, oral), marketed as Ubrelvy.

Registered studies
24
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Ubrogepant
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Migraine disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Calcitonin gene-related peptide (cgrp) antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli53.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae35.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis54.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

24registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Ubrogepant in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.3 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.3 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Ubrogepant with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

    NCT05125302 · start 2022-01-13

    Registered record
    Registry ID
    NCT05125302
    Conditions
    Migraine
    Interventions
    Ubrogepant; Placebo-Matching Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Recruiting
    Start
    2022-01-13
    Completion
    2027-05
    Enrolment
    1,059

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionUbrogepant; Placebo-Matching Ubrogepant
    PhasePhase 3
    Registry statusRecruiting

  • Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

    NCT04818515 · start 2021-03-17

    Registered record
    Registry ID
    NCT04818515
    Conditions
    Migraine
    Interventions
    Atogepant; Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-03-17
    Completion
    2021-06-18
    Enrolment
    26

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionAtogepant; Ubrogepant
    PhasePhase 1
    Registry statusCompleted

  • Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants

    NCT04492020 · start 2020-08-21

    Registered record
    Registry ID
    NCT04492020
    Conditions
    Migraine
    Interventions
    Ubrogepant 100 mg; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2020-08-21
    Completion
    2022-04-19
    Enrolment
    518

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionUbrogepant 100 mg; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety, Tolerability and Drug- Drug Interaction Study of Ubrogepant With Erenumab or Galcanezumab in Participants With Migraine

    NCT04179474 · start 2019-09-26

    Registered record
    Registry ID
    NCT04179474
    Conditions
    Migraine
    Interventions
    Ubrogepant; Erenumab; Galcanezumab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-09-26
    Completion
    2019-12-23
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionUbrogepant; Erenumab; Galcanezumab
    PhasePhase 1
    Registry statusCompleted

  • An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

    NCT02873221 · start 2016-09-13

    Registered record
    Registry ID
    NCT02873221
    Conditions
    Migraine, With or Without Aura
    Interventions
    Ubrogepant; Placebo-matching Ubrogepant; Usual Care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-09-13
    Completion
    2018-08-02
    Enrolment
    1,254

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine, With or Without Aura
    InterventionUbrogepant; Placebo-matching Ubrogepant; Usual Care
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine

    NCT02867709 · start 2016-08-26

    Registered record
    Registry ID
    NCT02867709
    Conditions
    Migraine, With or Without Aura
    Interventions
    Ubrogepant; Placebo-matching Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08-26
    Completion
    2018-02-26
    Enrolment
    1,686

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine, With or Without Aura
    InterventionUbrogepant; Placebo-matching Ubrogepant
    PhasePhase 3
    Registry statusCompleted

  • Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine

    NCT02828020 · start 2016-07-22

    Registered record
    Registry ID
    NCT02828020
    Conditions
    Migraine, With or Without Aura
    Interventions
    Ubrogepant; Placebo-matching Ubrogepant
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07-22
    Completion
    2017-12-14
    Enrolment
    1,672

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine, With or Without Aura
    InterventionUbrogepant; Placebo-matching Ubrogepant
    PhasePhase 3
    Registry statusCompleted

  • A Pharmacokinetic Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-007)

    NCT01657370 · start 2012-08

    Registered record
    Registry ID
    NCT01657370
    Conditions
    Migraine
    Interventions
    MK-1602; Placebo; Rescue medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-08
    Completion
    2012-12
    Enrolment
    195

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionMK-1602; Placebo; Rescue medication
    PhasePhase 2
    Registry statusCompleted

  • A Dose-Finding Study of MK-1602 in the Treatment of Acute Migraine (MK-1602-006)

    NCT01613248 · start 2012-07-01

    Registered record
    Registry ID
    NCT01613248
    Conditions
    Migraine
    Interventions
    MK-1602; Placebo-matching MK-1602; Rescue medication
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2012-07-01
    Completion
    2012-12-01
    Enrolment
    834

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMigraine
    InterventionMK-1602; Placebo-matching MK-1602; Rescue medication
    PhasePhase 2
    Registry statusCompleted